From GlobeNewswire: 2025-05-21 08:45:00

Silexion Therapeutics Corp completed a preclinical study evaluating SIL204’s potential in multiple cancers beyond pancreatic cancer, including colorectal and lung cancer. KRAS mutations are prevalent in these cancers, with global treatment markets worth over $30 billion annually. Silexion’s RNAi-based strategy aims to address the challenges of targeting KRAS variants with traditional approaches. The Company’s next-generation siRNA candidate, SIL204, has shown promise in preclinical studies, offering hope for improved outcomes in difficult-to-treat cancers. The detailed results of the study are expected to be announced in the coming days, potentially expanding Silexion’s development strategy.



Read more at GlobeNewswire: Silexion Therapeutics Completes Key Preclinical Studies